ScholarLens Back to search
2016•Neuro-OncologyOpen access

P16.01 Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial.

Roser Velasco, Sarah Besora, Cristina Santos, R. Sala, Cristina Izquierdo, Marta Simó, M. Gil, Beatriz Pardo, Eva Domingo, Jordi Bruna

Open full text 0 citations

Abstract

and symptoms should be considered as potentially paraneoplastic in the diagnostic workup.P16

Open-access reader

About this research paper

What this paper is about

and symptoms should be considered as potentially paraneoplastic in the diagnostic workup.P16

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

and symptoms should be considered as potentially paraneoplastic in the diagnostic workup.P16

Key concepts: Duloxetine, Chemotherapy-induced peripheral neuropathy, Peripheral neuropathy, Medicine, Chemotherapy, Clinical trial, Oncology, Peripheral

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
P16.01 Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial. — Research Paper | ScholarLens